Cystic Fibrosis
Conditions
Keywords
Cystic Fibrosis, Microbiome, Stratified Antibacterial therapy, Resistance, Pathogen Host Interaction
Brief summary
Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbation's caused by a multitude of organisms. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa. In acute CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CFMATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy.
Interventions
DRUGCeftazidime
DRUGTobramycin
Sponsors
Queen's University, Belfast
University of Paris 5 - Rene Descartes
University of Dundee
University of Washington
University Hospital Heidelberg
Teagasc
Clininfo S.A.
GABO:mi
Papworth Hospital NHS Foundation Trust
KU Leuven
Assistance Publique - Hôpitaux de Paris
European Union
University College Cork
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Written and informed consent, and assent where required. * Age 16 years or older at enrolment * Diagnosis of CF by standard sweat test and/or genetic analysis * Persistent pulmonary Pseudomonas aeruginosa colonization confirmed on at least 2 occasions in the preceding 12 months * Screening FEV1 predicted of \>25% * Able to perform spirometry reproducibly prior to enrolment * Able to expectorate and provide a sputum sample at least once daily * ≥1 non-elective course of intravenous antibiotics in the preceding year * Able to understand and comply with protocol requirements, restrictions and instructions and likely to complete the study as planned, as judged by the investigator
Exclusion criteria
* Life expectancy less than 6 months * They are a solid organ transplant recipient * Have a requirement for immunosuppression ≥10mg corticosteroids per day * Previous positive culture of non-tuberculosis mycobacteria species M.avium, M.abscessus or M.intracellulare within the last 12 months or undergoing active therapy * Positive culture of any Burkholderia cepacia species within the last 12 months or undergoing active therapy * Allergic bronchopulmonary aspergillosis on treatment * Known allergies to more than 3 different classes of antibiotics, and intolerance or allergy to tobramycin. * Liver portal hypertension, determined by identification of oesophageal varices * Advanced kidney disease requiring a dose reduction of ceftazidime or contraindicating aminoglycosides * History of any illness that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject * If patient undergoes a pulmonary exacerbation before the Microbiome analysis is reviewed by the Consensus Treatment Panel and i.v. antibiotics are administered. In this case, a repeat sputum will be sent for analysis 4 weeks after end of antibiotic treatment. * Pregnant or breast-feeding at time of eligible pulmonary exacerbation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage change in recovery (post-exacerbation) FEV1 relative to the previous pre-exacerbation FEV1. | Time from enrollment to 14 days post initiation of IV antibiotics for elligible exacerbation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The time to next pulmonary exacerbation | Time from pulmonary exacerbation day 0, to next pulmonary exacerbation up to study close month 21 | — |
| The improvement in symptom burden by day 7 as determined by Cystic Fibrosis Respiratory Symptom Diary (CFRSD) | Time from pulmonary exacerbation day 0 to day 7 of pulmonary exacerbation | As determined by Cystic Fibrosis Respiratory Symptom Diary (CFRSD) |
| Change in FEV1 | Time from enrollment in the study up to study close month 21 | — |
| Total number of i.v. antibiotic days (home or in hospital) from time of randomisation in the trial | Time from enrollment in the study up to study close month 21 | — |
| Total number of exacerbations post trial treatment | Time from pulmonary exacerbation day 0 to study close month 21 | — |
| The improvement in health related quality of life at day 28 post treatment and at 3 months as determined by the Cystic Fibrosis Questionnaire Revised (CFQR) | Time from pulmonary exacerbation day 0 to day 28 and month 3 post study treatment | As determined by the Cystic Fibrosis Questionnaire Revised (CFQR) |
Countries
Ireland
Outcome results
None listed